bullish
Concord Biotech (Pre-IPO): Niche Offering Amid Lean Competition to Drive Stable Growth
299 Views02 Aug 2023 18:16
SUMMARY
- Concord Biotech Ltd (658823Z IN) is amongst the few fermentation-based API manufacturing companies globally. The company commanded market share of 20%+ by volume in 2022 across identified fermentation‐based API products.
- Concord Biotech IPO opens for subscription on August 4. The IPO consists of offer for sale of 21M shares by Helix Investment Holdings at a price band of INR705–741/share.
- Large and growing addressable market, sizable market share, niche and limited competition offering, consistent growth and profitability, and reasonable valuation make the IPO worth of subscribing.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Concord Biotech Ltd (CONCORDB IN): Accelerated Growth Ahead; Recent Pullback Comforted Valuation11 Jun 2024
- Concord Biotech's US$650m Lock-Up Expiry - Some Could Be Tempted to Book Multi-Bagger Gains06 Feb 2024
- Concord Biotech Ltd (658823Z IN): Q2 EBITDA and PAT Triples on Operational Efficiencies01 Dec 2023
- Concord Biotech IPO - RHP Updates - Continued Growing Although Concentration Risk Remains Elevated02 Aug 2023
- Concord Biotech Pre-IPO - Sales Have Been Growing but Watch Out for Its High Concentration Risk30 Jan 2023
- Concord Biotech Pre-IPO Tearsheet24 Aug 2022
x